318 related articles for article (PubMed ID: 30852300)
21. Recurrent mutations refine prognosis in chronic lymphocytic leukemia.
Baliakas P; Hadzidimitriou A; Sutton LA; Rossi D; Minga E; Villamor N; Larrayoz M; Kminkova J; Agathangelidis A; Davis Z; Tausch E; Stalika E; Kantorova B; Mansouri L; Scarfò L; Cortese D; Navrkalova V; Rose-Zerilli MJ; Smedby KE; Juliusson G; Anagnostopoulos A; Makris AM; Navarro A; Delgado J; Oscier D; Belessi C; Stilgenbauer S; Ghia P; Pospisilova S; Gaidano G; Campo E; Strefford JC; Stamatopoulos K; Rosenquist R;
Leukemia; 2015 Feb; 29(2):329-36. PubMed ID: 24943832
[TBL] [Abstract][Full Text] [Related]
22. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
[TBL] [Abstract][Full Text] [Related]
23. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.
International CLL-IPI working group
Lancet Oncol; 2016 Jun; 17(6):779-790. PubMed ID: 27185642
[TBL] [Abstract][Full Text] [Related]
24. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.
Shindiapina P; Brown JR; Danilov AV
Br J Haematol; 2014 Oct; 167(2):149-61. PubMed ID: 25040077
[TBL] [Abstract][Full Text] [Related]
25. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia.
Cherng HJ; Jammal N; Paul S; Wang X; Sasaki K; Thompson P; Burger J; Ferrajoli A; Estrov Z; O'Brien S; Keating M; Wierda WG; Jain N
Br J Haematol; 2021 Jul; 194(1):61-68. PubMed ID: 33973230
[TBL] [Abstract][Full Text] [Related]
26. Cytogenetic Subclone Burden: A New Biomarker Predicting Chronic Lymphocytic Leukemia Patients Outcome.
Aref S; Mansour M; Abdel-Aziz S; Sabry M; Aref M; El Dosoky W
Asian Pac J Cancer Prev; 2024 Jan; 25(1):65-72. PubMed ID: 38285768
[TBL] [Abstract][Full Text] [Related]
27. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.
Baliakas P; Jeromin S; Iskas M; Puiggros A; Plevova K; Nguyen-Khac F; Davis Z; Rigolin GM; Visentin A; Xochelli A; Delgado J; Baran-Marszak F; Stalika E; Abrisqueta P; Durechova K; Papaioannou G; Eclache V; Dimou M; Iliakis T; Collado R; Doubek M; Calasanz MJ; Ruiz-Xiville N; Moreno C; Jarosova M; Leeksma AC; Panayiotidis P; Podgornik H; Cymbalista F; Anagnostopoulos A; Trentin L; Stavroyianni N; Davi F; Ghia P; Kater AP; Cuneo A; Pospisilova S; Espinet B; Athanasiadou A; Oscier D; Haferlach C; Stamatopoulos K;
Blood; 2019 Mar; 133(11):1205-1216. PubMed ID: 30602617
[TBL] [Abstract][Full Text] [Related]
28. Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone.
Marasca R; Maffei R; Martinelli S; Fiorcari S; Bulgarelli J; Debbia G; Rossi D; Rossi FM; Rigolin GM; Martinelli S; Gattei V; Del Poeta G; Laurenti L; Forconi F; Montillo M; Gaidano G; Luppi M
Hematol Oncol; 2013 Jun; 31(2):88-95. PubMed ID: 23027683
[TBL] [Abstract][Full Text] [Related]
29. The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation.
Visentin A; Bonaldi L; Rigolin GM; Mauro FR; Martines A; Frezzato F; Pravato S; Gargarella LR; Bardi MA; Cavallari M; Volta E; Cavazzini F; Nanni M; Facco M; Piazza F; Guarini A; Foà R; Semenzato G; Cuneo A; Trentin L
Haematologica; 2022 Apr; 107(4):868-876. PubMed ID: 34092056
[TBL] [Abstract][Full Text] [Related]
30. 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia.
Bagacean C; Tempescul A; Ternant D; Banet A; Douet-Guilbert N; Bordron A; Bendaoud B; Saad H; Zdrenghea M; Berthou C; Paintaud G; Renaudineau Y
J Immunother Cancer; 2019 Jan; 7(1):22. PubMed ID: 30696487
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
[TBL] [Abstract][Full Text] [Related]
33. Richter syndrome: A rare complication of chronic lymphocytic leukemia or small lymphocytic lymphoma.
Wąsik-Szczepanek E; Szymczyk A; Szczepanek D; Wszoła-Kleinrok J; Chocholska S; Pluta A; Hus M
Adv Clin Exp Med; 2018 Dec; 27(12):1683-1689. PubMed ID: 30156387
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG).
Jaramillo S; Agathangelidis A; Schneider C; Bahlo J; Robrecht S; Tausch E; Bloehdorn J; Hoechstetter M; Fischer K; Eichhorst B; Goede V; Hallek M; Döhner H; Rosenquist R; Ghia P; Stamatopoulos K; Stilgenbauer S
Haematologica; 2020 Nov; 105(11):2598-2607. PubMed ID: 33131249
[TBL] [Abstract][Full Text] [Related]
35. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.
Bühler A; Wendtner CM; Kipps TJ; Rassenti L; Fraser GA; Michallet AS; Hillmen P; Dürig J; Gregory SA; Kalaycio M; Aurran-Schleinitz T; Trentin L; Gribben JG; Chanan-Khan A; Purse B; Zhang J; De Bedout S; Mei J; Hallek M; Stilgenbauer S
Blood Cancer J; 2016 Mar; 6(3):e404. PubMed ID: 26967821
[TBL] [Abstract][Full Text] [Related]
36.
Campo E; Cymbalista F; Ghia P; Jäger U; Pospisilova S; Rosenquist R; Schuh A; Stilgenbauer S
Haematologica; 2018 Dec; 103(12):1956-1968. PubMed ID: 30442727
[TBL] [Abstract][Full Text] [Related]
37. The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13).
Dong HJ; Zhou LT; Zhu DX; Wang DM; Fang C; Zhu HY; Zhuang Y; Miao KR; Xu W; Li JY
Ann Hematol; 2011 Jun; 90(6):709-17. PubMed ID: 21113594
[TBL] [Abstract][Full Text] [Related]
38. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
39. The importance of complex karyotype in prognostication and treatment of chronic lymphocytic leukemia (CLL): a comprehensive review of the literature.
Jarošová M; Plevová K; Kotašková J; Doubek M; Pospíšilová Š
Leuk Lymphoma; 2019 Oct; 60(10):2348-2355. PubMed ID: 30773964
[TBL] [Abstract][Full Text] [Related]
40. Clinico-pathological impact of cytogenetic subgroups in B-cell chronic lymphocytic leukemia: experience from India.
Amare PS; Gadage V; Jain H; Nikalje S; Manju S; Mittal N; Gujral S; Nair R
Indian J Cancer; 2013; 50(3):261-7. PubMed ID: 24061469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]